LOGIN
Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma
August 2013
Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1
J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
246 patients with nonmetastatic osteosarcoma were randomized to evaluate the addition of ifosfamide to a primary chemotherapy regimen of methotrexate, cisplatin, and doxorubicin, with patients allocated to chemotherapy with or without ifosfamide. After a median follow-up of 76 months, there was no difference between groups in overall survival, event-free survival, and the percentage of patients wi...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.